Literature DB >> 11728421

Glycyrrhizin and some analogues induce growth of primary cultured adult rat hepatocytes via epidermal growth factor receptors.

M Kimura1, H Inoue, K Hirabayashi, H Natsume, M Ogihara.   

Abstract

We investigated the effects of glycyrrhizin (GL-1) and some analogues on DNA synthesis and proliferation in serum-free primary cultures of adult rat hepatocytes. The hepatocytes underwent DNA synthesis and proliferation in response to GL-1 and some analogues. The effects of these agents occurred in a time- and dose-dependent manner. The proliferative potency as judged by half-maximal effective concentrations was in the following order: 18-beta-H-glycyrrhetinic acid (GL-3; 4.5 x 10(-9) M)<18-beta-H-glycyrrhizin (GL-1; 4.4 x 10(-8) M)<18-alpha-H-glycyrrhetinic acid (GL-6; 6.0 x 10(-8) M). The analogue 18-alpha-H-glycyrrhetinic acid 3-O-beta-D-monoglucuronide (GL-5; 1.0 x 10(-7) M) weakly stimulated hepatocyte DNA synthesis and proliferation, whereas 18-alpha-H-glycyrrhizin (GL-4) and 18-beta-H-glycyrrhetinic acid 3-O-beta-D-monoglucuronide (GL-2) did not. The growth-promoting effects of GL-1, GL-3 and GL-6 were significantly inhibited at higher initial plating densities (7.0 x 10(4) and 10 x 10(4) cells/cm(2)). A monoclonal antibody against epidermal growth factor (EGF) receptor (1-100 ng/ml), but not that against EGF (1-100 ng/ml), dose-dependently inhibited glycyrrhizin- and analogue-induced hepatocyte DNA synthesis and proliferation. Specific inhibitors of growth-related signal transducers, such as genistein, PD98059 (2'-amino-3'-methoxyflavone) and rapamycin, completely blocked glycyrrhizin- and analogue-induced hepatocyte DNA synthesis and proliferation. Treatment of hepatocytes with GL-1, GL-3 and GL-6 rapidly stimulated tyrosine phosphorylation of the EGF receptor and p42 MAP kinase, which were inhibited by genistein and PD98059, respectively. These results suggest that glycyrrhizin and some analogues are primary hepatocyte mitogens that bind to EGF receptors and subsequently stimulate the receptor tyrosine kinase/mitogen-activated protein kinase pathway to induce hepatocyte DNA synthesis and proliferation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11728421     DOI: 10.1016/s0014-2999(01)01424-8

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  10 in total

1.  Severe cholestatic liver failure associated with gemcitabine adjuvant monotherapy for pancreatic cancer.

Authors:  Takaho Okada; Shinichi Egawa; Fuyuhiko Motoi; Kuniharu Yamamoto; Shigeru Ottomo; Naoaki Sakata; Toshiki Rikiyama; Yu Katayose; Michiaki Unno
Journal:  Clin J Gastroenterol       Date:  2011-10-01

2.  18α-Glycyrrhetinic Acid Proteasome Activator Decelerates Aging and Alzheimer's Disease Progression in Caenorhabditis elegans and Neuronal Cultures.

Authors:  Nikoletta Papaevgeniou; Marianthi Sakellari; Sweta Jha; Nektarios Tavernarakis; Carina I Holmberg; Efstathios S Gonos; Niki Chondrogianni
Journal:  Antioxid Redox Signal       Date:  2016-03-30       Impact factor: 8.401

3.  Possible pharmacotherapy for nifedipine-induced gingival overgrowth: 18α-glycyrrhetinic acid inhibits human gingival fibroblast growth.

Authors:  R Takeuchi; K Hiratsuka; K Arikawa; M Ono; M Komiya; Y Akimoto; A Fujii; H Matsumoto
Journal:  Br J Pharmacol       Date:  2016-02-03       Impact factor: 8.739

4.  Hepatic protection by glycyrrhizin and inhibition of iNOS expression in concanavalin A-induced liver injury in mice.

Authors:  Noriko Tsuruoka; Kazuki Abe; Kenjirou Wake; Masaru Takata; Akira Hatta; Tositugu Sato; Hideo Inoue
Journal:  Inflamm Res       Date:  2009-03-31       Impact factor: 4.575

5.  Central role of the EGF receptor in neurometabolic aging.

Authors:  Sana Siddiqui; Meng Fang; Bin Ni; Daoyuan Lu; Bronwen Martin; Stuart Maudsley
Journal:  Int J Endocrinol       Date:  2012-06-17       Impact factor: 3.257

6.  The use of Stronger Neo-Minophagen C, a glycyrrhizin-containing preparation, in robust neuroprotection in the postischemic brain.

Authors:  Seung-Woo Kim; Chae-Moon Lim; Hye-Kyung Lee; Ja-Kyeong Lee
Journal:  Anat Cell Biol       Date:  2011-12-30

7.  Viusid, a nutritional supplement, increases survival and reduces disease progression in HCV-related decompensated cirrhosis: a randomised and controlled trial.

Authors:  Eduardo Vilar Gomez; Yoan Sanchez Rodriguez; Ana Torres Gonzalez; Luis Calzadilla Bertot; Enrique Arus Soler; Yadina Martinez Perez; Ali Yasells Garcia; Maria Del Rosario Abreu Vazquez
Journal:  BMJ Open       Date:  2011-01-01       Impact factor: 2.692

8.  Apoptotic response through a high mobility box 1 protein-dependent mechanism in LPS/GalN-induced mouse liver failure and glycyrrhizin-mediated inhibition.

Authors:  Noriyuki Kuroda; Kouji Inoue; Tadayuki Ikeda; Yaiko Hara; Kenjiro Wake; Tetsuji Sato
Journal:  PLoS One       Date:  2014-04-01       Impact factor: 3.240

9.  Glycyrrhizin and related compounds down-regulate production of inflammatory chemokines IL-8 and eotaxin 1 in a human lung fibroblast cell line.

Authors:  Sachiko Matsui; Hiroatsu Matsumoto; Yoshiko Sonoda; Kumi Ando; Eriko Aizu-Yokota; Toshitsugu Sato; Tadashi Kasahara
Journal:  Int Immunopharmacol       Date:  2004-12-15       Impact factor: 4.932

10.  Glycyrrhizin prevents of lipopolysaccharide/D-galactosamine-induced liver injury through down-regulation of matrix metalloproteinase-9 in mice.

Authors:  Kazuki Abe; Tadayuki Ikeda; Kenjiro Wake; Tetsuji Sato; Toshitsugu Sato; Hideo Inoue
Journal:  J Pharm Pharmacol       Date:  2008-01       Impact factor: 3.765

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.